{"id":"W2600577610","doi":"10.1200/jco.2013.31.15_suppl.3515","title":"Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Bevacizumab; Medicine; Erlotinib; FOLFOX; KRAS; Internal medicine; Oncology; Clinical endpoint; FOLFIRI; Colorectal cancer; Population; Maintenance therapy; Panitumumab; Randomized controlled trial; Cancer; Chemotherapy; Oxaliplatin; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001805192,0.0007778121,0.001484401,0.0002251693,0.0001624511,0.0005777541,0.0007965983,0.0006492309,0.002138458],"category_scores_gemma":[0.001039926,0.000287679,0.001266192,0.0002340017,0.0004798147,0.0005097417,0.0003928366,0.001442346,0.0004146259],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00085151,"about_ca_system_score_gemma":0.0008543948,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001073445,"about_ca_topic_score_gemma":0.004164114,"domain_scores_codex":[0.9995493,0.0002507351,0.00002985649,0.00006060132,0.00004490312,0.00006443274],"domain_scores_gemma":[0.9995301,0.00008991425,0.000135243,0.00004728213,0.00002359126,0.0001738994],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.847914,0.008035037,0.007917185,0.0009762979,0.001989244,0.0000836598,0.0001378197,0.00163432,0.01061507,0.0002059143,0.003250964,0.1172405],"study_design_scores_gemma":[0.8040992,0.1683484,0.01987917,0.0001129134,0.001368611,0.0002706237,0.00005418219,0.001397084,0.001495432,0.0003096174,0.002635904,0.00002885614],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899327,0.006371037,0.0003701195,0.0004553309,0.00009065489,0.0005521242,0.0008424631,0.00007055613,0.001315085],"genre_scores_gemma":[0.991347,0.00220229,0.001249786,0.0007331575,0.0001023229,0.0007207131,0.002193238,0.00001605656,0.001435361],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002138458,"threshold_uncertainty_score":0.009546876,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.138055104141882,"score_gpt":0.4823168468310164,"score_spread":0.3442617426891345,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}